---
title: "Shandong Xinhua Pharmaceutical Company Limited (000756.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000756.SZ.md"
symbol: "000756.SZ"
name: "Shandong Xinhua Pharmaceutical Company Limited"
industry: "Pharmaceuticals"
datetime: "2026-03-07T01:12:02.811Z"
locales:
  - [en](https://longbridge.com/en/quote/000756.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000756.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000756.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000756.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000756.SZ.md)


# Shandong Xinhua Pharmaceutical Company Limited (000756.SZ)

## Company Overview

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People’s Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.xhzy.com](https://www.xhzy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-06T04:30:08.000Z

**Overall: B (0.39)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 31 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.89% |  |
| Net Profit YoY | -14.81% |  |
| P/B Ratio | 2.03 |  |
| Dividend Ratio | 1.63% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10545725296.87 |  |
| Revenue | 8487497875.06 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.63% | B |
| Profit Margin | 4.50% | C |
| Gross Margin | 19.75% | D |
| Revenue YoY | 1.89% | C |
| Net Profit YoY | -14.81% | D |
| Total Assets YoY | 3.05% | C |
| Net Assets YoY | 5.78% | B |
| Cash Flow Margin | 2222.80% | A |
| OCF YoY | 1.89% | C |
| Turnover | 0.95 | A |
| Gearing Ratio | 40.72% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shandong Xinhua Pharmaceutical Company Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.89%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-14.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.03",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.63%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10545725296.87",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8487497875.06",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.63%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "4.50%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "19.75%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "1.89%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-14.81%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.05%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.78%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "2222.80%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "1.89%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.95",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.72%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.04 | 67/222 | 28.79 | 26.15 | 23.28 |
| PB | 2.06 | 78/222 | 2.22 | 2.13 | 2.05 |
| PS (TTM) | 1.26 | 12/222 | 1.36 | 1.29 | 1.24 |
| Dividend Yield | 1.61% | 79/222 | 1.82% | 1.65% | 1.56% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | B | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | C | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Sell | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.71 |
| Highest Target | 10.50 |
| Lowest Target | 10.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000756.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000756.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000756.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000756.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**